<DOC>
	<DOC>NCT02674009</DOC>
	<brief_summary>The primary purpose for this study is to evaluate the duration of response defined as duration from first documented response of complete response (CR) or partial response (PR) until disease progression (as determined by the treating physician) for laBCC patients.</brief_summary>
	<brief_title>Observational Study to Determine the Effectiveness and Safety of Vismodegib in Patients With Locally Advanced Basal Cell Carcinoma (laBCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<criteria>Age &gt;/= 18 years IaBCC (inappropriate for surgery or radiotherapy) Patient is not included in any other trial Male or female patient is included in the pregnancy prevention program Patients, for whom treatment with Vismodegib is contraindicated according to the Summary of Product Characteristics (SmPC), which has been in effect at the time of treatment with Vismodegib, including: Hypersensitivity to the active substance or to any of the excipients Women who are pregnant or breastfeeding Women of childbearing potential who do not comply with the Vismodegib (ErivedgeÂ®) Pregnancy Prevention Programme Coadministration of St John's wort (Hypericum perforatum)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>